DGAP-Media / 02.07.2020 / 07:30
We are pleased to announce that our project company, inflamed pharma GmbH has received 70% of necessary funds from the Thüringer Aufbaubank. The grant is intended to cover the feasibility studies of our active ingredient, "valersan19" which treats inflammation and microcirculation disorders caused by COVID-19.
About inflamed pharma GmbH
inflamed pharma GmbH produces, researches and develops chemical and active pharmaceutical ingredients and is a pharmaceutical ingredient manufacturer of products applied in innovative therapies for human and veterinary medicine. One of these substances is an active pharmaceutical ingredient based on the active pharmaceutical ingredient substance procaine.
Procaine is a globally used active pharmaceutical ingredient substance in the category of local anesthetics, it is well-tested, low in side-effects and applied in various indications, for instance, in neural therapy. The application in relation with pain and inflammation such as arthritis and arthrosis is less established but crucial. Through the patented manufacturing process, the formerly solely parental available pharmaceutical ingredient is now useable for oral and dermal application and it is possible to realize synergistic effects in terms of impact. This is possible through an enhanced bioavailability. This technology of clustering, where the active pharmaceutical ingredient is integrated in a protecting shell, allows the transfer to other active pharmaceutical ingredients. This active pharmaceutical ingredient is currently used as extemporaneous mixture for manufacturing of pharmaceuticals of the inhouse production. Inflamed pharma GmbH is a GMP-certified manufacturer of active pharmaceutical ingredients and aims to conduct a clinical study in cooperation with University Hospital Jena, leading to the application for approval.
About Xlife Sciences AG
Xlife Sciences AG is a Swiss company with focus on investing in promising technologies in the life science industry. Xlife Sciences AG is building the bridge from research and development to healthcare markets by supporting researchers and entrepreneurs in positioning, structuring, developing and implementing their concepts. Together with industrial partners or universities, Xlife Sciences AG leads projects through the proof-of-concept phase after an invention disclosure or start-up. Subsequently, the firm focuses on out-licensing or selling the company, often with a combination of a strategic partnership. Xlife Sciences AG offers its investors direct access to the further development of innovative and future-oriented technologies at a very early stage.
For more information, please visit: www.xlifesciences.ch
End of Media Release
Issuer: Xlife Sciences AG
Key word(s): Research/Technology
02.07.2020 Dissemination of a Press Release, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de